Introduction
After the British Thoracic Association's short course chemotherapy trial, it was recommended that treatment with rifampicin (R) plus isoniazid (H) for nine months, together with ethambutol (E) for the initial two months, should be accepted as standard chemotherapy for pulmonary tuberculosis in the United Kingdom. ' This regimen has the advantage of using less toxic drugs and reducing the period of chemotherapy required from 18 months to nine, thereby theoretically increasing the likelihood of good compliance.
To assess how widely the recommended regimen has been adopted, and with what results, we have carried out a retrospective survey of the management of cases of tuberculosis in parts of Wales. KAREN 
Methods
The survey covered three years from 1 January 1976 to 31 December 1978 and included the five counties of south and west Wales, the population of which is just over 2 million. 2 Cases of tuberculosis were traced from three sources: (1) the Hospital Activity Analysis forms, on which the diagnosis is recorded at the time of the patient's discharge from hospital; (2) the Mycobacterium Reference Unit of the Public Health Laboratory Service in Cardiff; and (3) the notification lists of patients with tuberculosis from the medical officers for environmental health.
A complete list of patients who had tuberculosis in the three-year period of the survey was made for each county, and the list circulated to the medical records officers of each hospital and chest clinic within that county. The hospital or chest clinic was visited, and the notes of each patient on the list were reviewed.
Information taken from the notes included: (a) age and sex, (b) the basis for the diagnosis of tuberculosis, (c) the regimen prescribed and the duration of the treatment, (d) how well the patient complied with treatment (poor drug compliance was registered if the physician supervising treatment recorded it in the patient's notes or if the patient failed to attend clinic on two or more occasions without good reason), (e) number of deaths, (f) side effects of drugs, and (g) number of relapses.
Results
We reviewed the case notes of 753 patients. Age and sex- Table I shows the number of cases of tuberculosis within each age group and the incidence of tuberculosis related to the age of the population: 72%, of the patients were male, and 6 4% of all patients were non-Caucasian.
Basis for diagnosis-Mycobacterium tuberculosis was cultured from the sputum in 588 patients (78%), while 165 (22%) were culture Eighty-nine patients died during chemotherapy. Thirteen deaths were thought to be directly attributable to pulmonary tuberculosis. A further 89 patients did not comply with treatment, of whom 10 subsequently received supervised treatment. Of 10 poor compliers who died, seven deaths were thought to be directly attributable to tuberculosis. Eighteen patients were participating in the current British Thoracic Association's trial of six months' chemotherapy.3
The above 254 patients were omitted from analysis. rifampicin/isoniazid rifampicin (EHR/HR) or streptomycin-isoniazidrifampicin/isoniazid-rifampicin (SHR/HR) treatment for 9-12 months (regimen 2 Three patients received only one drug (regimen 10). Two (aged 5 and 6 years respectively) were thought after tuberculin skin test and chest x-ray examination to have primary tuberculosis. The third patient, a man of 64 with culture-positive pulmonary tuberculosis, received isoniazid alone after six weeks because of side effects to other drugs.
Two patients with culture-positive tuberculosis were not offered any treatment (regimen 11), one because the letter of referral to a chest physician went astray, and the other because the culture results appeared not to have been seen by the physician.
Five patients received ethambutol-isoniazid-rifampicin/ethambutolrifampicin (EHR/ER) treatment (regimen 12) for from 12 to 18 months.
The isoniazid was stopped in one patient because of side effects and in the other four patients because of primary drug resistance to isoniazid.
SIDE EFFECTS
Seventy-six patients (150) had side effects from their treatment, but 35 could continue the same treatment either after a brief interruption or after desensitisation to the offending drug. Treatment was changed in the remaining 41 patients (8°').
Side effects seen in patients receiving rifampicin and isoniazid included: asymptomatic rises in transaminases (18), jaundice (8), abdominal pains (2), Coomb's positive haemolytic anaemia (1), flu-like symptoms (2), pregnancy while taking oral contraceptive pill (1), and peripheral neuropathy (5). Three patients receiving ethambutol complained of blurred vision, but none had objective evidence of optic neuropathy. Four out of 11 patients receiving para-aminosalicylic acid had gastrointestinal upsets, while three patients had giddiness when taking streptomycin. Twenty-nine patients had drug rashes, fevers, or blood eosinophilias, but it was not clear from their case notes which drug was implicated.
Discussion
During the three-year period reviewed only 98 patients were treated with ethambutol-isoniazid-rifampicin/isoniazid-rifampicin for 9-12 months, the ethambutol being given for the initial two to three months. Thus Many physicians would accept that giving two drugs for an appropriate period to a patient with fully sensitive organisms would be adequate treatment. Most patients given two drugs, however, were assigned to such treatment before the sensitivities of the organisms were known. One patient proved to have resistant organisms and therefore received the equivalent of single-drug treatment. Of these 54 patients 37 had primary tuberculosis and, therefore, a presumed small bacterial population. Two children with primary tuberculosis received isoniazid alone, which many would consider inadequate treatment.
In their survey of pulmonary tuberculosis in Scotland, Heffernan et a17 8 reported that 4",, of patients died of active disease, 2"(' being diagnosed only after death. Ten years later, in our survey, mortality was similar (5%°,) with 20°' being diagnosed after death. In our survey 1-8(" died from tuberculosis while taking chemotherapy, contrasting with 1 90% in Heffernan's study7 and 11-0, and 1-20, in two recent studies by the British Thoracic Association. 3 Fox and Mitchison10 claimed that with the introduction of short-course chemotherapy default by patients would be of much less consequence therapeutically. We classified 89 patients (12%) as poor compliers, a very much higher figure than that seen in the two recent British Thoracic Association trials (5%O 9 and 303). This might imply that either better instructions, rapport, and doctor motivation are achieved in a trial, or that there may be some rejection of potential non-compliers from clinical trials. Of our 89 poor compliers, 43 were thought to have received a minimum of six months' treatment with 10 having supervised chemotherapy, although one of these patients did not receive his streptomycin because the district nurse considered it unnecessary. The British Thoracic Association's short-course study' suggested that 50% of patients receiving six months EHR/HR or SHR/HR would relapse, but surprisingly none of our poor compliers have relapsed as yet within this area of Wales. One patient, however, who reputedly had had at least 12 months' effective chemotherapy, had persistently positive sputum cultures.
Fox and Mitchison'0 also suggested that with shorter-course chemotherapy more resources could be concentrated on persuading patients to attend for regular follow-up. It was disappointing to see that of the 89 defaulters, 36 had stopped attending clinic within six months, with little evidence in their case notes that any attempt had been made to persuade them to continue their treatment.
Side effects from treatment were experienced by 150% of patients. Although many of these were minor, 8% had chemotherapy altered because of these side effects. This compares with an overall incidence of 10%, with 50%' requiring changes in treatment in the British Thoracic Association's recent six-month chemotherapy trial.3 In its previous short-course chemotherapy trial the EHR/HR regimen had been altered in 4% because of unwanted effects, and 8% of those receiving SHR/HR had had to have the streptomycin substituted by ethambutol.9 Part of the reason for the higher figures seen in our survey was our low threshold of recording side effects while reviewing notes, but it also appeared to us that some physicians had a low threshold for altering treatment in routine hospital practice. Another explanation for the differences in the alteration of drug regimens would be a high threshold before changing regimens during a trial.
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